RP3128
/ Rhizen
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 17, 2020
A first-in-human study to evaluate the safety, tolerability and pharmacokinetics of RP3128, an oral calcium release-activated calcium (CRAC) channel modulator in healthy volunteers.
(PubMed, J Clin Pharm Ther)
- P1/2 | "The safety, tolerability and PK/PD profile of RP3128 demonstrates its potential to be developed in inflammatory disorders and support further clinical development (ClinicalTrials.gov number: NCT02958982)."
Clinical • Journal • P1 data • PK/PD data • Immunology • Inflammation • IL4
1 to 1
Of
1
Go to page
1